Chennai-based Caplin Point Laboratories has allocated Rs 500-550 crore towards capex for the expansion of its existing capacities and additional manufacturing sites to augment product range. The capex, which will be financed exclusively through internal accruals also involves backward integration for major products.

The company is engaged in ongoing projects involving Phase-II & III expansion of the Caplin Steriles plant at Gummidipoondi in Tamil Nadu, general API manufacturing plant in Andhra Pradesh, manufacturing plant for oral solid dosages (OSD) and injectables for oncology near Chennai are expected to be completed by the current financial year.

Caplin would begin work on an oncology API manufacturing facility and another OSD facility in the first two quarters of FY25. Moreover, it completed expansion activities in the softgel manufacturing plant in Puducherry in Q4/FY23.

The company’s product portfolio includes tablets, capsules, injections, liquid orals, ointments and creams. As of now, Caplin Point and its subsidiary Caplin Steriles have manufacturing plants and facilities in six locations, including Tamil Nadu, Puducherry and Andhra Pradesh.